Bone Marrow Transplantation - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bone Marrow Transplantation - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bone Marrow Transplantation - Pipeline Review, H2 2014', provides an overview of the Bone Marrow Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bone Marrow Transplantation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bone Marrow Transplantation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bone Marrow Transplantation Overview 7
Therapeutics Development 8
Pipeline Products for Bone Marrow Transplantation - Overview 8
Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 9
Bone Marrow Transplantation - Therapeutics under Development by Companies 10
Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 11
Bone Marrow Transplantation - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Bone Marrow Transplantation - Products under Development by Companies 15
Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 16
Bone Marrow Transplantation - Companies Involved in Therapeutics Development 17
Mesoblast Limited 17
Cleveland BioLabs, Inc. 18
Compugen Ltd. 19
Pluristem Therapeutics Inc. 20
Spectrum Pharmaceuticals, Inc. 21
TikoMed AB 22
Taiga Biotechnologies, Inc. 23
Bone Marrow Transplantation - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
melphalan - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Allogeneic MPC for Bone Marrow Transplantation - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TM-400 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PLX-BMP - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CBLB-612 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CBLB-612 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CGEN-15001 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Central Memory T Cell Therapy for Bone Marrow Transplantation - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Protein for Bone Marrow Transplantation - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Bone Marrow Transplantation - Recent Pipeline Updates 49
Bone Marrow Transplantation - Dormant Projects 55
Bone Marrow Transplantation - Discontinued Products 56
Bone Marrow Transplantation - Product Development Milestones 57
Featured News & Press Releases 57
Apr 23, 2014: Spectrum Pharmaceuticals' Pivotal Trial of Captisol-Enabled Melphalan Meets Primary Endpoint 57
Nov 13, 2013: Improved Survival In Children With Life Threatening Graft Versus Host Disease Reported After Treatment With Mesoblast's Cell Therapy 58
Nov 04, 2013: Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients 59
Oct 29, 2013: Pharmalink Receives US Orphan Drug Designation for Busulipo, its Novel Oncology Product for Bone Marrow Transplantation 59
Sep 03, 2013: BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells 60
May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 61
Nov 06, 2012: Cleveland BioLabs Announces Publication Of Studies On Effect Of Entolimod On Graft-versus-tumor Activity In Models Of Allogeneic Bone Marrow Transplantation 62
Oct 24, 2012: Enlivex Therapeutics Completes Clinical Trial For Treatment Of Bone Marrow Transplant Recipients, Reports Positive Results 62
Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 63
Aug 06, 2012: Pluristem's PLX Cells Save Life Of Cancer Patient Suffering From Bone Marrow Failure 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Number of Products under Development for Bone Marrow Transplantation, H2 2014 8
Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Bone Marrow Transplantation - Pipeline by Mesoblast Limited, H2 2014 17
Bone Marrow Transplantation - Pipeline by Cleveland BioLabs, Inc., H2 2014 18
Bone Marrow Transplantation - Pipeline by Compugen Ltd., H2 2014 19
Bone Marrow Transplantation - Pipeline by Pluristem Therapeutics Inc., H2 2014 20
Bone Marrow Transplantation - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 21
Bone Marrow Transplantation - Pipeline by TikoMed AB., H2 2014 22
Bone Marrow Transplantation - Pipeline by Taiga Biotechnologies, Inc., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Bone Marrow Transplantation Therapeutics - Recent Pipeline Updates, H2 2014 49
Bone Marrow Transplantation - Dormant Projects, H2 2014 55
Bone Marrow Transplantation - Discontinued Products, H2 2014 56